Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfgang Willenbacher

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Memo|April 3, 2018
Short overview on the current standard of treatment in newly diagnosed multiple myelomaElla Willenbacher, Agnes Balog, Wolfgang Willenbacher
Acta Haematologica|November 8, 2014
B cell lymphoma with lung involvement: what is it about?Michael Mian, Ines Wasle, Stefan Gritsch, et al.
Anticancer Research|April 12, 2015
Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasoneNormann Steiner, David Nachbaur, Paul König, et al.
Plos One|March 4, 2016
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma TherapeuticsElla Willenbacher, Roman Weger, Ursula Rochau, et al.
Annals of Hematology|October 20, 2019
Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemiaElla Willenbacher, Karin Jöhrer, Wolfgang Willenbacher, et al.
Wiener Klinische Wochenschrift|January 8, 2013
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemiaChristine Valentiny, Martina Mitrovic, Lisa Pleyer, et al.
International Journal of Technology Assessment in Health Care|March 10, 2016
LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGYAnna Nachtnebel, Johanna Breuer, Wolfgang Willenbacher, et al.
Annals of Hematology|July 3, 2020
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomasElla Willenbacher, Wolfgang Willenbacher, Roman Weger, et al.
Current Medical Research and Opinion|March 1, 2013
Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational studyMichael Fiegl, Günther G Steger, Michael Studnicka, et al.
Journal of Medical Economics|April 11, 2019
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and ItalyEvangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Memo|April 3, 2018
Short overview on the current standard of treatment in newly diagnosed multiple myelomaElla Willenbacher, Agnes Balog, Wolfgang Willenbacher
Acta Haematologica|November 8, 2014
B cell lymphoma with lung involvement: what is it about?Michael Mian, Ines Wasle, Stefan Gritsch, et al.
Anticancer Research|April 12, 2015
Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasoneNormann Steiner, David Nachbaur, Paul König, et al.
Plos One|March 4, 2016
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma TherapeuticsElla Willenbacher, Roman Weger, Ursula Rochau, et al.
Annals of Hematology|October 20, 2019
Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemiaElla Willenbacher, Karin Jöhrer, Wolfgang Willenbacher, et al.
Wiener Klinische Wochenschrift|January 8, 2013
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemiaChristine Valentiny, Martina Mitrovic, Lisa Pleyer, et al.
International Journal of Technology Assessment in Health Care|March 10, 2016
LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGYAnna Nachtnebel, Johanna Breuer, Wolfgang Willenbacher, et al.
Annals of Hematology|July 3, 2020
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomasElla Willenbacher, Wolfgang Willenbacher, Roman Weger, et al.
Current Medical Research and Opinion|March 1, 2013
Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational studyMichael Fiegl, Günther G Steger, Michael Studnicka, et al.
Journal of Medical Economics|April 11, 2019
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and ItalyEvangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, et al.
Pageof 8